Medical News

RSS

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling.

16 Mar 2011

MorphoSys inks manufacturing agreement with Boehringer Ingelheim

MorphoSys AG and Boehringer Ingelheim announced today the signing of a biopharmaceutical manufacturing agreement for therapeutic antibodies. The agreement covers the process development and manufacturing of additional clinical material for MorphoSys's proprietary MOR208 program and other drug candidates. MOR208, a potent monoclonal anti-CD19 antibody, is in development for the treatment of chronic lymphocytic leukemia and potentially other B-cell malignancies. The program is currently being evaluated in a phase 1 clinical trial in the USA by MorphoSys's partner Xencor Inc.

16 Mar 2011

Fibrocell Science submits azficel-T final study report to FDA

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has submitted a final study report to the U.S. Food & Drug Administration (FDA) for a completed, six-month histological study examining skin after injections of azficel-T.

16 Mar 2011

Study: Dried plums more safe, effective than psyllium to treat constipation

Given their palatability, tolerability and availability, dried plums should be considered the initial approach to the management of mild to moderate constipation in the general population, according to results of a randomized clinical trial recently published in Alimentary Pharmacology and Therapeutics.

16 Mar 2011

Genesis Biopharma to establish Adoptive Cell Immunotherapy based therapeutic development program

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, today announced it is expanding its therapeutic strategy to include active immunotherapies to treat various cancers. The Company will focus on establishing a therapeutic development program based on Adoptive Cell Immunotherapy.

16 Mar 2011

Lantheus proposes $150 million 9.750% Senior Notes offering

Lantheus Medical Imaging, Inc. today announced that it intends to offer $150 million in aggregate principal amount of its 9.750% Senior Notes due 2017 (the "New Notes"). The New Notes are being offered as additional debt securities under an indenture pursuant to which Lantheus previously issued $250 million in aggregate principal amount of 9.750% Senior Notes due 2017.

16 Mar 2011

PHC announces acquisition of MeadowWood Behavioral Health

PHC, Inc., d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, today announced that it has signed an agreement to acquire MeadowWood Behavioral Health, located in New Castle, Delaware, for $21.5 million, subject to customary purchase price adjustments. The transaction is expected to close late in the second quarter of 2011.

16 Mar 2011

St. Jude Medical achieves 2 million mechanical heart valve implant milestone

St. Jude Medical, Inc., a global medical device company, today announced that the company will celebrate the treatment of more than 2 million patients with its mechanical heart valve technology. This milestone, a landmark achievement for prosthetic heart valves, demonstrates the company's commitment to cardiac surgery and improving patient outcomes.

16 Mar 2011

RegeneRx RGN-352 Phase 2 trial in acute myocardial infarction placed on clinical hold

RegeneRx Biopharmaceuticals, Inc. announced that it has received a notice from the U.S. Food and Drug Administration (FDA) indicating that, due to non-compliance with FDA's current Good Manufacturing Practice (cGMP) regulations by its contract manufacturer, the Company's Phase 2 clinical trial of RGN-352, its injectable formulation of Thymosin beta 4 for the treatment of acute myocardial infarction (AMI), has been placed on clinical hold.

16 Mar 2011

Oxford Nanopore selects Accelrys Pipeline Pilot NGS Collection as preferred analysis platform

Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.

From Oxford Nanopore Technologies 16 Mar 2011

Finesse releases T700 upstream processing platform for single-use bioreactors

Finesse Solutions, LLC, San Jose, CA, a manufacturer of measurement and control solutions for life sciences process applications, announced the release of the T700™ upstream processing platform for single-use bioreactors ranging from 25L to 2,000L in size. The T700 family of turn-key control systems is designed to the highest performance and quality standards.

16 Mar 2011

First Edition: March 16, 2011

Today's headlines include reports about how some states are putting "their own spin" on health law implementation as well as other developments related to Medicaid cuts, health law waiver tallies and more.

16 Mar 2011

BistroMD releases exclusive videos to educate women on menopause, weight gain

BistroMD, the number one physician-designed, chef-prepared meal delivery company in the United States, is releasing a series of exclusive videos where the company's founding physician, Caroline J. Cederquist, M.D., educates women on how to cope with menopause and weight gain.

16 Mar 2011

Aerocrine and Meditab partner for Allergy offices across the US.

Aerocrine AB today announced the launch of a strategic alliance with Meditab Software Inc. at the American Association of Allergy, Asthma and Immunology annual meeting in San Francisco on March 19-21.

16 Mar 2011

Scientists create new drug delivery system to treat cancer

Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.

16 Mar 2011

FUJIFILM submits Aspire HD FFDM system 510(k) application to FDA for marketing clearance

FUJIFILM Medical Systems U.S.A., Inc. today announced the submission to the United States Food and Drug Administration of its 510(k) application for marketing clearance of its new Aspire HD Full Field Digital Mammography system.

16 Mar 2011

Cortex enters agreement with Biovail to regain AMPAKINE assets and rights

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc., to regain the AMPAKINE® assets and rights related to respiratory depression.

16 Mar 2011

Light files contractual lawsuit against Creation in Tel-Aviv District Court

Light Instruments Ltd., a subsidiary company of Syneron Medical Ltd. and a leading manufacturer of the LiteTouch and Laser-in-Handpiece dental laser breakthrough technologies has filed a lawsuit on March 9, 2011, at the Tel-Aviv District Court, against Creation S.r.l., an Italian company, headed by its CEO, Professor Alfred Resch.

16 Mar 2011

Nukepills.com donates 50,000 potassium iodide tablets to Tokushukai Hospital in Tokyo

Approximately 50,000 potassium iodide tablets have been donated by Nukepills.com to Tokushukai Hospital in Tokyo, Japan for immediate distribution to those affected by Japan's nuclear reactor crisis.

16 Mar 2011

NIFA grants $3.7 million to Temple's CORE for childhood obesity research

Temple's Center for Obesity Research and Education recently received a five year, $3.7 million grant from the USDA's National Institute of Food and Agriculture to fund a project aimed at preventing obesity among low-income pre-schoolers.

16 Mar 2011